Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene

• Autorzy: M. Baranska , K. Lewandowski , M. Gniot , M. Iwola , Lewandowska. , M. Komarnicki
• Języki publikacji: EN

Abstrakty

EN

Point mutations of bcr-abl tyrosine kinase are the most frequent causes of imatinib resistance in chronic myeloid leukaemia (CML) patients. In most CML cases with BCR-ABL mutations leading to imatinib resistance the second generation of tyrosine kinase inhibitors (TKI- e.g. nilotinib or dasatinib) may be effective. Here, we report a case of a CML patient who during imatinib treatment did not obtain clinical and cytogenetic response within 12 months of therapy. The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). After 1 month of nilotinib therapy a rapid progression of clinical symptoms was observed. In the presence of the F359I point mutation only dasatinib treatment overcame imatinib and nilotinib resistance.

Słowa kluczowe

EN

BCR-ABL ONCOGENE; DIRECT SEQUENCING; KINASE INHIBITOR; MUTATION; MYELOID LEUKEMIA

• Czasopismo: Journal of Applied Genetics
• Rocznik: 2008
• Tom: 49
• Numer: 2
• Strony: 201-203

Twórcy

autor

M. Baranska

autor

K. Lewandowski

autor

M. Gniot

autor

M. Iwola

autor

Lewandowska.

autor

M. Komarnicki

• Typ dokumentu: ARTICLE
• Bibliografia: Marta Baranska, Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60?569 Poznan, Poland